ALDH1A1 and breast carcinoma: In 2016, Kida et al. analyzed 234 breast cancer patients who were treated with neoadjuvant chemotherapy, and they found that in ALDH1(+) cases, the pathological complete response (pCR) was significantly lower (13.5% vs. 30.3%) [74].